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Abstract
Background: Pregnancies resulting through oocyte donation have been associated with increased risk for adverse
outcomes for the mother, such as gestational hypertensive disorders. However, little is known about possible neonatal
complications of such pregnancies. The purpose of this study was to evaluate the neonatal health outcomes among
singleton pregnancies in a population of relatively young and healthy oocyte recipients in Sweden, taking into account
the medical indication leading to treatment.
Methods: This cohort study involved 76 women conceiving with donated oocytes, 149 age-matched nulliparous
women conceiving spontaneously and 63 women conceiving after non-donor IVF. Participants were recruited
during 2005–2008 and followed up until delivery. Data on neonatal outcomes were retrieved from the National
Birth Medical Register and the medical records of oocyte recipients from seven Swedish University Hospitals with
IVF clinics. Logistic regression analyses were performed to examine the association of mode of conception and
neonatal outcomes, adjusted for maternal age and BMI, gestational age and delivery by cesarean section.
Results: Infants conceived through oocyte donation had higher odds for premature delivery [OR 2.36, 95 % CI
(1.02–5.45)], for being small for gestational age [OR 4.23, 95 % CI (1.03–17.42)] and having Apgar score below
7 at 5 min [OR 10.57, 95 % CI (1.21–92.20)] compared to spontaneously conceived infants. Similar trends were
observed when comparing infants conceived through oocyte donation to those conceived by traditional IVF.
Furthermore, donor oocyte infants had a lower mean birthweight and length compared to autologous oocyte
neonates (p = 0.013); however no differences were noted among infants born at term. Neonatal outcomes were more
favorable among women with diminished ovarian reserve compared to those with other indications for oocyte donation.
Conclusions: Infants conceived after oocyte donation in Sweden have higher odds of being born prematurely
and having lower mean birthweight in comparison to non-donor infants.
It seems that these unfavorable neonatal outcomes are present despite the age, weight and health restrictions
applied to recipients before oocyte donation treatment in Sweden.
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Background
Oocyte donation is a well established-widely applied
infertility treatment for women with premature idio-
pathic, iatrogenic and even natural menopause, with
more than 30.437 cycles per year being performed in
Europe during 2012 [1]. Previous studies have reported an
association between oocyte-donation pregnancies and an
increased occurrence of hypertensive disorders of preg-
nancy [2–9], gestational diabetes [10], placental abnormal-
ities [9, 11, 12], preterm delivery [2, 4, 11–13], prolonged
maternal hospitalization after delivery and increased
prevalence of caesarean section [4, 7, 13].
Regarding neonatal complications, the outcomes
seem to be overall reassuring especially among single-
ton deliveries. The prevalence of major congenital mal-
formations [6, 10] as well as the Apgar score [2, 4, 6]
were noted to be comparable to that in the general
population. However conflicting findings have been re-
ported regarding neonatal hospital stay [2, 14, 15],
birthweight [2, 4, 5, 9, 15, 16], rate of low birthweight
(i.e. birthweight <2500 gr) [4, 5, 9, 17] and small for
gestational age (SGA) infants [5, 15, 16]. In fact, in the
recent meta-analysis by Adams et al. [18] the significant
findings include being born with low birthweight
(<2500 g), very low birthweight (<1500 g), preterm
(<37th week), with lower gestational age and preterm
with low birthweight when compared with autologous
oocyte counterparts. Some of the unfavorable outcomes
have previously been attributed mostly to advanced ma-
ternal age, as well as the presence of multifetal preg-
nancies and prematurity as a consequence [13, 18].
Prompted by the observations mentioned above, we
aimed to examine if medically indicated oocyte donation
is associated with increased risk for adverse neonatal
outcomes in singleton pregnancies in a population of
relatively young and healthy oocyte recipients in Sweden
and whether this is affected by treatment indication.
Methods
Study sample and data collection
The present observational cohort study is a sequel to
the study evaluating the obstetric outcomes in pregnan-
cies resulting from oocyte donation by Elenis et al. [7]
and is part of the larger cohort study ”Swedish multicenter
study on gamete donation” [19]. During the period 2005–
2008, consecutive couples starting concurrently IVF treat-
ment with either donated or autologous oocytes at
University Hospitals in Stockholm, Gothenburg, Uppsala,
Umeå, Linköping, Örebro and Malmö (Sweden) were
approached regarding participation. In particular, women
undergoing IVF with donated oocytes (n = 238) vs
women treated with autologous oocytes (n = 233) were
originally approached, a proportion of which (63 % vs
51 % respectively) were included in the larger cohort.
Only women who became pregnant with autologous
or donated oocytes and delivered singletons during
the study period were included in this sequel study.
All participating women were enrolled just once in
the study and no repeat pregnancies were included.
The Index group (n = 76) is composed of women re-
ceiving treatment with donated oocytes who later gave
birth to a singleton. In order to assess differences in out-
come, two comparison groups were used;
a) Comparison group A (CgA) (n = 149) comprises
nulliparous women with spontaneously conceived
pregnancies, singleton deliveries and no history of
subfertility found in the medical register. Women
in Comparison group A were matched to the
Index group in regard to age in three categories,
≤29, 30–34, ≥35 years, at a ratio of 2:1. With the
exception of the eligibility criteria according to
the study design, Comparison group A was
otherwise randomly selected.
b) Comparison group B(CgB) (n = 63) comprises women
undergoing IVF treatment with their own gametes
due to couple infertility who conceived with singleton
pregnancies at the University hospitals mentioned
above. Women undergoing IVF with partner’s sperm
were included as a Comparison group in order to
assess if the adverse outcomes for oocyte recipients
reported formerly can be credited solely to donation
or perhaps even to the characteristics of the infertile
couple, the underlying infertility and/or the use of
assisted reproductive techniques [20]. Age matching
was not performed.
All participants in Index and Comparison group B
could communicate adequately in Swedish [19] and in-
formed consent was obtained after written and oral in-
formation was given to the participants. No personal
information on participants of Comparison group A was
received and thus personal informed consent was not re-
quired for that group. Due to study design (i.e. being a
sequel of the larger multicenter study on gamete dona-
tion), as well as the lack of appropriate and robust publi-
cations on the field before conducting this study, no
power calculation had been performed a priori. All
medical data analyzed were retrieved from the Swedish
Medical Birth Register (MBR), which is a validated
register including information on prenatal, delivery and
neonatal care [21, 22]. Additional medical information
for the oocyte recipients was extracted from the treat-
ment protocols that are part of the medical records at
each center.
The estimation of gestational age at delivery for
women conceiving spontaneously was calculated mainly
based on second-trimester ultrasound scan (which is
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attended by 98 % of pregnant women during 16th-
19th gestational week) [23] or on last menstrual
period (if ultrasound scan was unavailable). For
women subjected to conventional IVF and oocyte do-
nation treatment, gestational age was estimated based
on the date of the embryo transfer. All medical out-
comes studied were retrieved from the MBR and the
diagnosis according to the 10th version of the Inter-
national Classification of Diseases (ICD-10) that the
woman or infant had received perinatally (i.e. through
pregnancy and up to 28 days after delivery). The set
of neonatal variables explored was selected based on
prior Swedish register studies (MBR) and other inter-
national studies on the field [18, 21]. No information
was retrieved from the medical records of the neo-
nates. It should be added that the rate of Small for
Gestational Age (SGA) (i.e. weight for gestational age
corresponding to more than two standard deviations
below the Swedish growth standard) [24] was calcu-
lated either through ultrasound measurements ante-
natally or by comparing the expected weight to the
actual birthweight postnatally.
Medical background characteristics
Maternal background characteristics are presented with
detailed demographic and clinical data in the preceding
publication by Elenis et al. [7]. Briefly, the study groups
did not differ significantly regarding the health status of
the participants (data not shown); the only exception be-
ing hypothyroidism (7 oocyte recipients vs 1 person in
Comparison group A and 0 in Comparison group B),
nearly half of which could be credited to Turner syn-
drome, probably due to meticulous preconceptional
health control of Turner women in Sweden [25]. The
chronic medical conditions reported were otherwise pre-
viously described in detail by Elenis et al. [7]. Physicians
at the Swedish university fertility clinics are practically
unanimous in taking the position that women with
serious intercurrent diseases should be denied gamete
donation treatment; thus, only women with ascertained
health status were included in the Index group. Regard-
ing parity, the entire Comparison group A were nullipar-
ous, in contrast to 92.1 % of participants in Comparison
group B and 92.1 % of women in the Index group (data
not shown) [7]. Additionally, oocyte recipients were di-
agnosed more frequently with hypertensive disorders of
pregnancy compared to naturally conceiving women
(15.8 % versus 6 %; p = 0.017) (data not shown) [7]. A
summary of the most important baseline characteristics
of the index and comparison groups is included even in
this publication (Table 1).
Our study does not include any incidents of maternal
death. However, one case of in utero stillbirth in the 29th
week of gestation in Comparison group A was observed
(excluded in the current sequel substudy) [7]. Although
the original cohort is the same, the calculations differ
since one participant was excluded due to stillbirth as
mentioned above.
Finally, since previous reports have found a negative
association between diminished ovarian reserve and
birthweight [26], we chose to include in our study the
medical indication leading to oocyte donation [7]. The
most common reason for receiving donated oocytes in
our study group was premature ovarian insufficiency
(POI) or being “poor responder” defined according to
the Bologna criteria [27] (37/76, 48.7 %), followed by
Turner syndrome (10/76, 13.2 %); bilateral oophorec-
tomy or post chemotherapy (9/76, 11.8 %); ”egg factor”
(6/76, 7.9 %); multiple unsuccessful IVF cycles (5/76,
6.6 %) or genetic reasons (5/76, 6.6 %). Only 4 persons
could not be classified according to the above categories
(5.3 %). For more details please see the publication by
Elenis et al. [7]. It should be added that “egg factor” is a
generally poorly defined category associated with suffi-
cient quantity but somehow defective quality of oocytes
resulting in infertility.
Table 1 Maternal baseline characteristics between Index group (oocyte donation group) and Comparison group A (women having
conceived spontaneously) and B (women having conceived through IVF)
Index group Comparison group A (CgA) Comparison group B (CgB) p-value Index vs CgA p-value Index vs CgB
n % n % n %
Maternal age (yrs)
<35 36/76 47.4 81/149 54.4 42/63 66.7 p = 0.321 p = 0.002
≥35 40/76 52.6 68/149 45.6 21/63 33.3
Maternal BMI(kg/m2)
<25 33/70 47.1 87/132 65.9 40/62 64.5 p = 0.010 p = 0.045
≥25 37/70 52.9 45/132 34.1 22/62 35.5
Caesarean Section
No 34/76 44.7 110/149 73.8 51/63 81.0 p = 0.000 p = 0.000
Yes 42/76 55.3 39/149 26.2 12/63 19.0
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Statistical analysis
Data analysis was conducted using IBM SPSS v.20 (IBM
Inc., Armonk, NY, USA). Statistical significance was set
at a p-value of <0.05 (two-sided) in all analyses.
The association between various neonatal outcomes
and Index/Comparison group status was evaluated by
first comparing Index women (oocyte recipients) to
Comparison group A (spontaneously pregnant women)
and then to Comparison group B (women having con-
ceived with conventional IVF). Normality of the data
was evaluated using the Shapiro-Wilk test. The groups
were compared with the use of Mann Whitney U test
(for continuous variables non-normally distributed), Chi
square or Fisher’s exact test (for categorical variables) as
well as logistic regression analyses; a single regression
model without adjustment for socio-demographic factors,
as well as a multivariate logistic regression model. Covari-
ates likely to affect the outcomes were chosen based on
results from prior studies and are included in the multi-
variate logistic regression model: maternal age as com-
pleted years on delivery day (two categories, <35 years or
≥35 years); body mass index (BMI, kg/m2) defined as BMI
recorded at first antenatal visit (two categories, <25 kg/m2
or ≥ 25 kg/m2) [28]; gestational age at delivery as a con-
tinuous variable and delivery by caesarean section (no/
yes). When studying outcomes such as SGA & LGA diag-
nosis and preterm delivery, the multivariate regression
model was not adjusted for gestational length, since by
definition the variables were already corrected for gesta-
tional age. After employing a path diagram (such as
DAGitty graphic model) preeclampsia was considered as a
mediator between mode of conception and neonatal out-
comes and was therefore not selected as a confounder to
be included in the statistical models. Women who con-
ceived spontaneously or by conventional IVF (Comparison
group A and B respectively) were chosen as reference
groups in the logistic regression models. The results were
expressed as odds ratios (OR) and the corresponding 95 %
confidence intervals (CI) were estimated.
Finally, a within-group analysis regarding the most fre-
quent neonatal outcomes and Index/Control status was
performed by group comparison with Chi-square or
Fisher’s exact test (for categorical variables) or Mann
Whitney U test (for numerical variables non-normally
distributed). More specifically, the Index group after be-
ing divided in two subgroups including women with “di-
minished ovarian reserve” or “other indication” for OD
treatment was compared in turn to Comparison group
A with regard to various neonatal outcomes.
Results
The maternal baseline characteristics of the Index and
Control women are presented in Table 1. Oocyte recipi-
ents have a more advanced age compared to Comparison
group B, are more often overweight or obese and deliver
more often by cesarean section compared to both Com-
parison groups (Table 1).
Neonatal outcomes are presented in Tables 2 and 3
where infants of oocyte recipients are compared to infants
who were conceived spontaneously and after conventional
IVF, respectively. Regarding perinatal mortality, one
neonatal death associated to chromosome deletion
occurred within the Index group; the infant was deliv-
ered in the 34th gestational week and died shortly after.
No associations were found between groups regarding
the prevalence of congenital malformations, neonatal
jaundice, hypoglycemia, LGA diagnosis and ten-minute
Apgar score. To note, no difference was observed re-
garding the length of neonatal hospital stay after birth
between Index and Comparison groups; the latter did
not differ even after studying a subgroup of solely non-
healthy children (data not shown).
More specifically, mean birthweight and length dif-
fered between Index and Comparison group A as a
whole [(3238 ± 840) vs (3495 ± 693), (p = 0.013) and
(50 ± 3.5) vs (51 ± 3), (p = 0.011) respectively]; never-
theless no differences were noted among term infants
(i.e. gestational length ≥37 weeks at birth) in these
groups [(3380 ± 795) vs (3512 ± 668), (p = 0.126) and
(50 ± 4) vs (51 ± 3), (p = 0.056) respectively] (Table 2).
However when the effect estimate was evaluated more
thoroughly in a logistic regression model, the effect
size was found to be subtle (i.e. OR close to one) and
disappeared after adjusting for gestational length (data
not shown). Additionally, the Index group had a higher
incidence of SGA diagnosis (8 % vs 2 %, p = 0.064) and
prematurity (17.1 % vs 8.1 %, p = 0.041) in relation to
Comparison group A. Moreover, neonates conceived
after oocyte donation had more frequently five-minute
Apgar score (AS) below 7 compared to spontaneously
conceived infants (6.7 % vs 0.7 %, p = 0.017), a portion
of which were also born preterm (4 out of 5 neonates
conceived through OD). However, the risk for the
above conditions did not remain statistically significant
after adjustment for the covariates named previously
(i.e. maternal age, maternal BMI, gestational age, de-
livery by cesarean section) (Table 2).
Regarding infants conceived through oocyte donation
or autologous IVF, no differences were noted with re-
spect to head circumference, birthweight and length, in-
dependently if infants were born at term or preterm
(p > 0.05) (Table 3). On the contrary, neonatal asphyxia
(7.9 % vs 0 %, p = 0.032), low birthweight (<2500 gr)
(10.5 % vs 1.6 %, p = 0.040) and prematurity (17.1 % vs
4.8 %, p = 0.031) were more frequently diagnosed among
infants conceived through oocyte donation compared to
Comparison group B; the above risks however did not
differ after adjustment.
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Table 2 Neonatal outcomes of infants conceived through oocyte donation (Index group) or conceived spontaneously
(Comparison group A)
Index group Comparison group A
Median (IQR) Range Median (IQR) Range
Gestational length 40 (4) 28–42 40 (3) 28–43
Head circumference, cm 35 (3) 25–38 35 (2) 25–40
Birth Length, cm* 50 (3.5) 39–54 51 (3) 32–56
Birth Length term infants, cm 50 (4) 45–54 51 (3) 42–56
Birthweight, grams* 3238 (840) 1105–4910 3495 (693) 730–5800
Birthweight term infants, grams 3380 (795) 2284–4910 3512 (668) 2200–5800
n % n % Unadjusted OR (95 % CI) Adjusteda OR (95 % CI)
Perinatal death (<7 days after birth) 1/76 0/149
Congenital malformationa
No 68/72 94.4 134/139 96.4 1.58 1.37
Yes 4/72 5.6 5/139 3.6 (0.41–6.06) (0.23–8.14)
5 min Apgar sa
≥7 70/75 93.3 148/149 99.3 10.57 7.01
<7 5/75 6.7 1/149 0.7 (1.21–92.20) (0.40–123.43)
10 min Apgar s
≥7 74/75 98.7 148/148 100.0 – –
<7 1/75 1.3 0 0.0
Asphyxiaa
No 70/76 92.1 145/149 97.3 3.11 2.49
Yes 6/76 7.9 4/149 2.7 (0.85–11.37) (0.52–12.00)
Preterm delivery (<37w)b
No 63/76 82.9 137/149 91.9 2.36 2.24
Yes 13/76 17.1 12/149 8.1 (1.02–5.45) (0.87–5.81)
LGAb
No 74/75 98.7 145/149 97.3 0.49 0.32
Yes 1/75 1.3 4/149 2.7 (0.05–4.46) (0.03–3.46)
SGAb
No 69/75 92.0 146/149 98.0 4.23 3.39
Yes 6/75 8.0 3/149 2.0 (1.03–17.42) (0.59–19.69)
Low birthweighta
<2500 gr 8/76 10.5 8/149 5.4 2.07 0.65
≥2500 gr 68/76 89.5 141/149 94.6 (0.75–5.76) (0.10–4.30)
Jaundicea
No 74/76 97.4 146/149 98.0 1.32 1.62
Yes 2/76 2.6 3/149 2.0 (0.22–8.05) (0.23–11.68)
Hypoglycemiaa
No 73/76 96.1 145/149 97.3 1.49 1.74
Yes 3/76 3.9 4/149 2.7 (0.33–6.83) (0.25–12.03)
Gender of the childa
Boy 39/76 51.3 71/149 47.7 0.86 0.85
Girl 37/76 48.7 78/149 52.3 (0.50–1.50) (0.45–1.60)
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Finally, we compared the commonest neonatal out-
comes after taking into account the medical indication
of oocyte donation treatment. Our findings suggest that
neonates born to women receiving treatment based on
“other indication” have lower mean birthweight and
length, as well as higher rate of SGA diagnosis, com-
pared to neonates of women with diminished ovarian re-
serve or fertile women (Table 4). However no statistical
difference is noted regarding birthweight and length
when women with Turner syndrome are excluded from
the “other indication” subgroup (data not shown). Five
minute Apgar score below 7 (AS < 7 at 5 min) occurred
more often on the “Diminished Ovarian Reserve” sub-
group compared to “other indication of treatment” sub-
group or Comparison group A (8.3 % vs 5.9 % vs 0.7 %
respectively); a proportion of the latter can be associated
to prematurity (i.e. preterm/total neonates with AS < 7
at 5 min: 2/3(66.7 %), 2/2(100 %) and 0/1(0 %) in each
group respectively) (data not shown).
Discussion
Our data suggest that neonates conceived through oo-
cyte donation are more frequently born preterm
(<37 weeks) and have a lower mean birthweight and
length compared to infants conceived spontaneously.
The somatic measurements are nonetheless improved
among term infants independently of mode of concep-
tion. The results that are of borderline statistical signifi-
cance indicate a notable trend but possibly reflect the
limited sample size. Although our findings conform to
those of previous published studies [4–6], as well as with
the latest and largest meta-analysis in the field [18], one
can still reflect on the clinical significance of such subtle
birthweight differences. It seems however safer to con-
clude that there is an increasing body of evidence point-
ing in the direction of a pragmatic negative association
between oocyte donation-gestational length and fetal
growth which may be considered much more important
in the long term prognosis of these infants.
Notably, a higher prevalence of hypertensive disor-
ders of pregnancy is observed among women conceiv-
ing after oocyte donation [7, 8]. It still remains
unclear whether and at which degree hypertension or
preeclampsia in relation to the mode of conception
might act synergistically affecting gestational length or
leading to growth restriction due to utero-placental
insufficiency.
Contrary to other studies [2, 4], a five-minute Apgar
score below 7 was more frequent among infants con-
ceived through oocyte donation; the effect, however, dis-
appears when gestational age is taken into account,
possibly reflecting the effect of prematurity. No differ-
ences were noted regarding the presence of congenital
malformations in our study; one should however be cau-
tious in the interpretation of these results since that
might reflect limited statistical power.
Further analyses within the oocyte donation group re-
vealed that birthweight and length is lower after preg-
nancies with treatment indications other than
diminished ovarian reserve. Our finding, which comes
in contrast to the study by Keegan et al. [26], can pos-
sibly be attributed to the high proportion of women
with Turner syndrome in our sample, since no neonatal
somatometric differences are noted after excluding
those women. However, women with Turner syndrome
constitute an important part of the oocyte recipient
population; we chose as a consequence not to exclude
them from the study population and the analysis pre-
sented. To note, neonatal outcomes similar to those in
the Turner subgroup in our study were observed in the
Turner syndrome study by Hagman et al. carried out in
Scandinavia [25]. Finally, in contrast to Anttila et al.
[14] and Cobo et al. [15], the duration of hospital stay
in a newborn surveillance unit did not differ between
Index and Comparison groups.
Although the exact underlying pathophysiological
mechanisms remain obscure, OD pregnancies show a
greater degree of antigenic dissimilarity i.e. HLA mis-
match in peripheral blood compared to IVF with autolo-
gous oocytes or spontaneously conceived pregnancies
[29, 30]. Placentas from OD pregnancies, examined his-
tologically and immunohistochemically, exhibited in-
creased diffuse chronic deciduitis with dense fibrinoid
deposition in the basal plate of the placenta, as well as
increased infiltration by mononuclear cells compared to
non-donor IVF pregnancies [31]. The corresponding
pattern of immune mediated placental pathology is con-
sidered a unique sign of donated oocyte conception and
is postulated to be representative of a type of ”host-ver-
sus-graft reaction” [4].
Table 2 Neonatal outcomes of infants conceived through oocyte donation (Index group) or conceived spontaneously
(Comparison group A) (Continued)
Infant Hospital stay, daysa
0–2 41/68 60.3 102/139 72.3 1.72 1.13
≥3 27/68 39.7 39/139 27.7 (0.94–3.17) (0.56–2.31)
aAdjusted for maternal age when giving birth (< or ≥ 35 yrs), maternal BMI (< or ≥25 kg/m2), gestational age (continuous variable) and cesarean section (no/yes)
bAdjusted for maternal age when giving birth (< or ≥ 35 yrs), maternal BMI (< or ≥25 kg/m2) and cesarean section (no/yes)
* p < 0.05
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Table 3 Neonatal outcomes of infants conceived through oocyte donation (Index group) or conceived through conventional IVF
(Comparison group B)
Index group Comparison group B
Median (IQR) Range Median (IQR) Range
Gestational length 40 (4) 28–42 39 (2.3) 36–42
Head circumference, cm 35 (3) 25–38 35 (3) 30–38
Birth Length, cm 50 (3.5) 39–54 50 (3.3) 44–56
Birth Length term infants, cm 50 (4) 45–54 50 (3) 44–56
Birthweight, grams 3238 (840) 1105–4910 3545 (785) 1985–5420
Birthweight term infants, grams 3380 (795) 2284–4910 3585 (743) 1985–5420
n % n % Unadjusted OR (95 % CI) Adjusted OR (95 % CI)
Perinatal death (<7 days after birth) 1/76 0/63
Congenital malformationa
No 68/72 94.4 56/60 93.3 0.82 0.32
Yes 4/72 5.6 4/60 6.7 (0.20–3.44) (0.05–2.05)
5 min Apgar sa
≥7 70/75 93.3 62/63 98.4 4.43 1.24
<7 5/75 6.7 1/63 1.6 (0.50–38.94) (0.11–14.18)
10 min Apgar s
≥7 74/75 98.7 61/61 100.0 – –
<7 1/75 1.3 0 0.0
Asphyxia
No 70/76 92.1 63/63 100.0 – –
Yes 6 7.9 0 0.0
Preterm delivery (<37w)b
No 63/76 82.9 60/63 95.2 4.13 4.35
Yes 13/76 17.1 3/63 4.8 (1.12–15.21) (1.08–17.52)
LGAb
No 74/75 98.7 60/63 95.2 0.27 0.09
Yes 1/75 1.3 3/63 4.8 (0.03–2.67) (0.01–1.06)
SGAb
No 69/76 92.0 62/63 98.4 5.39 1.70
Yes 6/76 8.0 1/63 1.6 (0.63–46.04) (0.16–17.72)
Low birthweighta
<2500 gr 8/76 10.5 1/63 1.6 7.29 0.50
≥2500 gr 68/76 89.5 62/63 98.4 (0.89–59.99) (0.02–13.81)
Jaundicea
No 74/76 97.4 59/63 93.7 0.40 0.32
Yes 2/76 2.6 4/63 6.3 (0.07–2.25) (0.04–2.44)
Hypoglycemiaa
No 73/76 96.1 60/63 95.2 0.82 0.44
Yes 3/76 3.9 3/63 4.8 (0.16–4.22) (0.07–2.90)
Gender of the child
Boy 39/76 51.3 31/63 49.2 0.92 0.70
Girl 37/76 48.7 32/63 50.8 (0.47–1.79) (0.32–1.52)
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The principal strength of this report lies in its research
design, being a national-level study. Since it was not car-
ried out at a single setting for ART, the results are not
reflective of specific treatment protocols or embryology
laboratory techniques. Regarding reproductive health,
the public health insurance program in Sweden covers
all gamete donation treatment costs, providing the op-
portunity for citizens to equally benefit, independent of
their financial ability. Moreover, the maternal health care
system is organized within a well-developed and easily
available primary care sector with standardized and free
of charge antenatal care carried out mainly by commu-
nity midwives with referral for obstetric assessment by
physicians when potential complications are detected
[32]. Thus, the contrasting outcomes cannot be solely at-
tributed to the different level of obstetric or neonatal
care provided to the three study groups. Furthermore,
previously reported unfavorable findings have been
questioned due to the presence of multiple confounding
factors (i.e. maternal comorbidities, advanced maternal
age, multiple gestations) [13, 18]. Luckily, the latter does
not apply for the nationwide oocyte donation program
in Sweden. The participating University clinics that
make the eligibility evaluation of the recipients, seem to
be in agreement regarding the importance of age and
weight restrictions (age < 40 years and BMI < 35 kg/m2),
as well as good health status of the oocyte recipients
[33]. It is therefore important to note that the neonatal
outcomes in our index population were observed in spite
of the eligibility criteria adopted by healthcare practi-
tioners in Sweden, introducing oocyte donation as an in-
dependent risk factor.
The limitations of the study include the limited sample
size and low statistical power as seen by the wide confi-
dence intervals; thus, further studies in similar settings
are needed to confirm our findings. On the other side,
there is only one similar study which comprised Finnish
participants, but it was smaller, dates back to 1998, and
uses only IVF pregnancies as control group [14]. Based
on the fact that most studies included in a recent meta-
analysis come from the United States [18], we feel that
the information presented herein, originating from a
country with a different health care system, might be a
valuable input in the literature and can contribute in
Table 3 Neonatal outcomes of infants conceived through oocyte donation (Index group) or conceived through conventional IVF
(Comparison group B) (Continued)
Infant Hospital stay, daysa
0–2 41/68 60.3 40/58 69.0 1.46 0.94
≥3 27/68 39.7 18/58 31.0 (0.70–3.06) (0.38–2.30)
aAdjusted for maternal age when giving birth (< or ≥ 35 yrs), maternal BMI at first antenatal visit (< or ≥25 kg/m2), gestational age (continuous variable) and
cesarean section (no/yes)
bAdjusted for maternal age when giving birth (< or ≥ 35 yrs), maternal BMI at first antenatal visit (< or ≥25 kg/m2) and cesarean section (no/yes)
Table 4 Neonatal outcomes studied by indication of oocyte donation treatment compared to spontaneously conceived infants
(Comparison group A)
Comparison group A(CgA) “Diminished ovarian
reserve” subgroup (DOR)




n (%) n (%) n (%)
Congenital malformation 5/139 3.6 % 3/35 8.6 % 1/32 3.1 % 0.202 1.000
1 min Apgar s <7 9/149 6 % 5/36 13.9 % 4/34 11.8 % 0.110 0.266
5 min Apgar s <7 1/149 0.7 % 3/36 8.3 % 2/34 5.9 % 0.024 0.089
10 min Apgar s <7 0/148 – 0/36 – 1/34 2.9 % – 0.187
Preterm delivery (<37w) 12/149 8.1 % 6/37 16.2 % 6/34 17.6 % 0.133 0.090
SGA diagnosis 3/149 2 % 1/36 2.8 % 5/34 14.7 % 0.583 0.006
Median (IQR) Range Median (IQR) Range Median (IQR) Range
Head circumference 35 (2) 25–40 35 (2.75) 30–38 34.5 (4) 27–38 0.792 0.107
Birthweight 3472.5 (704) 730–5800 3550 (913) 2005–4910 3080 (801) 1105–4670 0.458 0.004
Birthweight term infants 3512 (668) 2200–5800 3622.5 (931.3) 2720–4910 3270 (686) 2284–4670 0.898 0.034
Birth Length 51 (3) 32–56 50 (5) 45–54 49 (3.25) 39–54 0.662 0.001
Birth length term infants 51 (3) 42–56 51 (4.25) 45–54 50 (2.75) 45–54 0.832 0.011
“Diminished ovarian reserve” subgroup includes women with Premature Ovarian Insufficiency (POI) or those who are poor responders
”OD other” subgroup includes all other indications (i.e. women with Turner syndrome, after oophorectomy or chemotherapy, genetic reasons, multiple
unsuccessful IVF, ”egg factor”)
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more robust conclusions in future review and meta-
analytic approaches. Although we do not report a large
enough series on infants conceived through oocyte do-
nation treatment to permit statistically safe conclusions,
our results conform to the latest international scientific
data [18].
Additionally, a possible limitation is that the birth-
weight analysis in this study was not adjusted for
cryopreservation (i.e. fresh vs cryopreserved embryos)
or in vitro culture length, which are both believed to
affect birthweight probably through epigenetic alter-
ations. However, current data suggest that neither
birthweight, nor preterm delivery among infants con-
ceived after oocyte donation differ between fresh or
frozen-thawed cycles [15, 34, 35] or between embryos
transferred at different developmental stages [34]. Finally,
although outcome variables in the Swedish national health
registers are regarded as highly valid [21], the lack of more
detailed information from participants’ hospital medical
records remains a limitation.
Conclusion
Infants conceived after oocyte donation have higher
odds of prematurity and lower mean birthweight in
this nation-wide study, in spite of the generally good
health status and relatively young age of the Swedish
oocyte recipients. Although the findings are of con-
cern, their clinical relevance is still dubious. Couples
receiving treatment with donated oocytes should
nonetheless receive preconception counseling and in-
dividualized antenatal monitoring.
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